Phanes Therapeutics Announces Clinical Supply Agreement with Roche to Evaluate PT217 in Combination with an anti-PD-L1 Therapy May 15, 2024
Ph 3 KeyVibe-010 Trial of Vibostolimab + Pembrolizumab coformulation as Adjuvant Treatment for Resected High-Risk Melanoma unlikely to achieve a statistically significant RFS improvement May 15, 2024
VERSATILE-002 Ph 2 Trial Meets Primary Study Endpoints in 1l Recurrent/Metastatic HPV16-Positive Head and Neck Cancer May 15, 2024
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA May 15, 2024
5 patients deaths reported the next day after update provided on Interim TAMARACK Ph 2 Study Data May 15, 2024
FAILED TRIAL: Ph 3 KEYNOTE-B21 trial of adjuvant KEYTRUDA + chemo +/- RT did not meet primary endpoint of DFS in newly diagnosed, high-risk endometrial cancer after surgery with curative intent May 15, 2024
U.S. FDA Accepts and grants Priority Review of BLA for Zeno for the Treatment of NRG1+ NSCLC and PDAC May 15, 2024
FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer May 15, 2024
Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in interim assessment of Ph 2 GALAXIES Lung-201 May 15, 2024
Positive Ph 1/2 Data for GT-30 Trial of Personalized Therapeutic Cancer Vaccine Announced May 15, 2024
Higher AML Complete Remission (CR) Rates and Significant Durability Reported with Additional Interim Subject Data May 15, 2024
